Journal article
Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta‐analysis
Abstract
BACKGROUND: Warfarin and aspirin (acetylsalicylic acid [ASA]) are the most commonly used anticoagulant and antiplatelet drugs in the treatment of cardiovascular disease.
OBJECTIVES: To provide a pooled estimate of the bleeding risk from randomized controlled trials (RCTs) comparing warfarin and ASA at the dose ranges recommended in evidence-based guidelines.
Authors
WARKENTIN AE; DONADINI MP; SPENCER FA; LIM W; CROWTHER M
Journal
Journal of Thrombosis and Haemostasis, Vol. 10, No. 4, pp. 512–520
Publisher
Elsevier
Publication Date
4 2012
DOI
10.1111/j.1538-7836.2012.04635.x
ISSN
1538-7933
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAged, 80 and overAnticoagulantsAspirinBlood CoagulationConfidence IntervalsEvidence-Based MedicineFemaleFibrinolytic AgentsHemorrhageHumansIntracranial HemorrhagesMaleMiddle AgedOdds RatioPlatelet Aggregation InhibitorsPractice Guidelines as TopicRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsThrombosisTreatment OutcomeWarfarin